Triazenes pp 45-62 | Cite as

Antimestastatic Action of Triazene Derivatives

  • Tullio Giraldi
  • Laura Perissin
  • Sonia Zorzet
  • Valentina Rapozzi

Abstract

Dimethyltriazenes have gained, since the original observation in 1962 by Shealy et al. on the antitumor action of DTIC in mice (1), a definite position among antineoplastic drugs because of the established activity of DTIC against human malignant melanoma, as well as against other human malignancies when used in combination with other antitumor drugs. Substituted benzenoid dimethyltriazenes have also been thoroughly examined in experimental animal tumor systems, and selected compound(s) are currently under clinical trials as second generation substitutes for DTIC (see other chapters in this volume).

Keywords

Hydrolysis Toxicity Leukemia Oncol Dimethyl 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Y.F. Shealy, J.A. Montgomery and W.R. Laster Jr., Antitumor activity of triazenoimidazoles, Biochem. Pharmacol. 11; 674 (1962).PubMedCrossRefGoogle Scholar
  2. 2).
    J. Heyes, Antimetastatic effect of 4-carbethoxy-5(3,3-dimethyl-1-triazeno)-2-methylimidazole, J. Natl. Cancer Inst. 53: 279 (1974).PubMedGoogle Scholar
  3. 3).
    T. Giraldi, P. J. Houghton, D. M. Taylor and C. Nisi, Antimetastatic action of some triazene derivatives against the Lewis lung carcinoma in mice, Cancer Treat. Rep. 62: 721 (1978).PubMedGoogle Scholar
  4. 4).
    T. Giraldi, G. Sava, R. Cuman, C. Nisi and L. Lassiani, Selectivity of the antimetastatic and cytotoxic effects of 1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt, (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane, and cyclophosphamide in mice bearing Lewis lung carcinoma, Cancer Res. 41: 2524 (1981).PubMedGoogle Scholar
  5. 5).
    G. Sava, T. Giraldi, L. Lassiani and C. Nisi, Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma, Cancer Res. 44: 64 (1984).PubMedGoogle Scholar
  6. 6).
    T. Colombo, S. Garattini, L. Lassiani and M. D’Incalci, Activity of 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt in M 5076/73A ovarian reticular cell sarcoma of the mouse, Cancer Treat. Rep. 66:1945 (1982).PubMedGoogle Scholar
  7. 7).
    T. Giraldi, G. Sava, L. Perissin, S. Zorzet, M. Tamaro and L. Dolzani, DTIC e suoi derivati: farmaci citotossici o antimetastatici?, Giornale Italiano di Chemiote rapia 32: 43 (1985).Google Scholar
  8. 8).
    L. Lassiani, C. Nisi, T. Giraldi, G. Sava and R. Cuman, Selective antimetastatic triazenes: a quantitative approach, Quant. Struct.-Act. Relat. 3: 59 (1984),CrossRefGoogle Scholar
  9. 9).
    G. Sava, T. Giraldi, L. Lassiani and R. Dogani, Effects of isomeric aryldimethyltriazenes on Lewis lung carcinoma growth and metastases in mice, Chem. Biol. Interactions 46: 131 (1983).CrossRefGoogle Scholar
  10. 10).
    A. Gescher and M. D. Threadgill, The metabolism of triazene antitumor drugs, Pharmac. Ther. 32: 191 (1987).CrossRefGoogle Scholar
  11. 11).
    G. F. Kolar and R.Z. Preussmann, Validity of a linear Hammet plot for the stability of some carcinogenic 1-aryl-3,3-dimethyltriazenes in aqueous system, Z. Naturforsch. 26b: 950 (1971).Google Scholar
  12. 12).
    T. Giraldi, A. M. Guarino, C. Nisi and G. Sava, Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma, Pharmacol. Res. Commun. 12: 1 (1980).PubMedCrossRefGoogle Scholar
  13. 13).
    G. Sava, T. Giraldi, L. Lassiani and C. Nisi, Metabolism and mechanism of the antileukemic action of isomeric aryldimethyltriazenes, Cancer Treat. Rep. 66: 1751 (1982).PubMedGoogle Scholar
  14. 14).
    G. Sava, T. Giraldi, L. Lassiani and C. Nisi, Mechanism of the antimetastatic action of dimethyltriazenes, Cancer Treat. Rep. 63: 93 (1979).PubMedGoogle Scholar
  15. 15).
    B. L. Pool, Microsomal mediated metabolism of dialkylaryltriazenes. I. Demethylation of ring-halogenated 3,3-dimethyltriazenes, J. Cancer Res. Clin. Oncol. 93: 215 (1979).PubMedCrossRefGoogle Scholar
  16. 16).
    B. L. Pool, Microsomal mediated metabolism of dialkylaryltriazenes. II. Isolation and identification of metabolites of 3,3-dimethyl-l-phenyltriazene, J. Cancer Res. Clin. Oncol. 93: 221 (1979).PubMedCrossRefGoogle Scholar
  17. 17).
    T. Giraldi, C. Nisi and G. Sava, Investigation on the oxidative N-demethylation of aryl triazenes in vitro, Biochem. Pharmacol. 24: 1793 (1975).PubMedCrossRefGoogle Scholar
  18. 18).
    G. Sava, S. Zorzet, L. Perissin, T. Giraldi, L. Lassiani, Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes, Cancer Chemother. Pharmacol. 21: 241 (1988).PubMedCrossRefGoogle Scholar
  19. 19).
    G. Abel, T. A. Connors and T. Giraldi, In vitro metabolic activation of l-p-carboxamidophenyl-3,3-dimethyl triazene to cytotoxic products, Cancer Letters 3: 259 (1977).CrossRefGoogle Scholar
  20. 20).
    G. Sava, T. Giraldi, L. Lassiani, C. Nisi and P. B. Farmer, Mechanism of the antileukemic effects of 1-p-carboxamidophenyl-3,3-dimethyltriazene and its in vitro metabolites, Biochem. Pharmacol. 31: 3629 (1982).PubMedCrossRefGoogle Scholar
  21. 21).
    M. B. Donati, A. Poggi, L. Mussoni, G. deGaetano and S. Garattini, Hemostasis and experimental cancer dissemination, in: “Cancer invasion and metastasis: biological mechanism and therapy,” S. B. Day, W. P, L. Myers, P. Stansly, S. Garattini and M. G. Lewis, eds., Raven Press, New York (1977).Google Scholar
  22. 22).
    M. B. Donati, J. F. Davidson and S. Garattini, “Malignancy and the hemostatic system,” Raven Press, New York (1981).Google Scholar
  23. 23).
    P. Hilgard and R. D. Thornes, Anticoagulants in the treatment of cancer, Eur. J. Cancer 12: 755 (1976).CrossRefGoogle Scholar
  24. 24).
    B. Maat and P. Hilgard, Anticoagualnts and experimental metastases; evaluation of antimetastatic effects in different model systems, J. Cancer Res. Clin. Oncol. 101: 275 (1981).PubMedCrossRefGoogle Scholar
  25. 25).
    T. Giraldi, G. Sava, E, Mitri and R. Cherubino, Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma, Eur. J. Cancer Clin. Oncol. 20: 961 (1984).PubMedCrossRefGoogle Scholar
  26. 26).
    T. Giraldi, G. Sava, R. Cherubino, G. Bottiroli and G. Mazzini, Effects of DTIC, DM-COOK and ICRF-159 on the number of circulating Lewis lung carcinoma cells detected by flow cytometry, Clin. Expl. Metastasis 2: 151 (1984).CrossRefGoogle Scholar
  27. 27).
    B. S. Wang, G. A. McLoughlin, J. P. Richie and J. A. Mannick, Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines, Cancer Res. 40: 288 (1980).PubMedGoogle Scholar
  28. 28).
    B. F. Sloane, J. R. Dunn and K. V. Honn, Lysosomal cathepsin B: correlation with metastatic potential, Science 212: 1151 (1981).PubMedCrossRefGoogle Scholar
  29. 29).
    D. Tarin, B. J. Hoyt and D. J. Evans, Correlation of collagenase secretion with metastatic-colonization potential in naturally occuring murine mammary tumours, Br. J. Cancer 46: 266 (1982).PubMedCrossRefGoogle Scholar
  30. 30).
    B. U. Pauli, D. E. Schwartz, E. J. M. Thonar and K. E. Kuettner, Tumor invasion and host extracellular matrix, Cancer Metastasis Rev. 2: 129 (1983).PubMedCrossRefGoogle Scholar
  31. 31).
    T. Giraldi and G. Sava, Malignancy and tumor proteinases: effects of proteinase inhibitors, in: “Proteinases and their inhibitors. Structure, function and applied aspects,” V. Turk and Lj. Vitale, eds., Mladinska knjiga-Pergamon Press, Ljubljana-Oxford, (1981).Google Scholar
  32. 32).
    T. Giraldi, G. Sava, L. Perissin and S. Zorzet, Primary tumor growth and formation of spontaneous lung metastases in mice bearing Lewis lung carcinoma treated with proteinase inhibitors, Anticancer Res. 4: 221 (1984).PubMedGoogle Scholar
  33. 33).
    T. Giraldi, C. Nisi and G. Sava, Antimetastatic effects of N-diazoacetyl-glycine derivatives in C57BL mice, J. Natl. Cancer Inst. 58: 1129 (1977).PubMedGoogle Scholar
  34. 34).
    T. Giraldi, A. M. Guarino, C. Nisi and L. Baldini, Selective antimetastatic effects of N-diazoacethylglycine derivatives in mice, Europ. J. Cancer 15: 603 (1979).CrossRefGoogle Scholar
  35. 35).
    T. Giraldi, G. Sava and C. Nisi, Mechanism of the antimetastatic action of N-diazoacetylglycinamide in mice bearing Lewis lung carcinoma, Europ. J. Cancer 16: 87 (1980).CrossRefGoogle Scholar
  36. 36).
    A. J. Salsbury, K. Burrage and K. Hellmann, Histological analysis of the antimetastatic effect of (±)1,2-bis(3,5-dioxopiperazin-1-yl)propane, Cancer Res. 34: 843 (1974).PubMedGoogle Scholar
  37. 37).
    G. Sava and T. Giraldi, Antitumor effects of Ganu and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice, Cancer Chemother. Pharmacol. 10: 167 (1983).PubMedCrossRefGoogle Scholar
  38. 38).
    T. Giraldi, G. Sava, L. Lassiani e C. Nisi, Effetti di farmaci antitumorali sulla crescita e formazione di metastasi di tumori sperimentali, in: “Apporto della ricerca di base al controllo della crescita neoplastica, Vol. I” Idelson, Napoli (1981).Google Scholar
  39. 39).
    F. Bartoli-Klugmann, G. Decorti, L. Perissin, S. Zorzet, G. Sava and T. Giraldi, Effects of antineoplastic drugs on the proteolytic activity of murine metastasizing tumors, Chemioterapia II: 363 (1983).Google Scholar
  40. 40).
    T. Giraldi, G. Sava, L. Perissin and S. Zorzet, Proteinases and proteinase inhibition by cytotoxic and antimetastatic drugs in transplantable solid metastasizing tumors in mice, Anticancer Res. 5: 355 (1985).PubMedGoogle Scholar
  41. 41).
    J. F. DiStefano, G. Beck, B. Lane and S. Zucker, Role of tumor cell membrane-bound serine proteases in tumor-induced target cytolysis, Cancer Res. 42: 207 (1982).PubMedGoogle Scholar
  42. 42).
    F.S. Steven, B.S. Brown, T.P. Hulley, S. Itzahaki, T. Giraldi and L. Lassiani, Inhibition of cell-surface neutral protease of Ehrlich ascites tumour cells by potassium p-(3,3-dimethyl-l-triazeno)benzoate, Biochemistry International 11: 153 (1985).PubMedGoogle Scholar
  43. 43).
    T. Giraldi, G. Sava, L. Perissin, S. Zorzet and F.S. Steven, Tumor cell metastasis and surface neutral proteinase: effects on antimetastatic and antitumor drugs, Invasion Metastasis 5: 336 (1985).PubMedGoogle Scholar
  44. 44).
    T. Giraldi, G. Sava, M. Kopitar, A. Suhar, V. Turk and A. Baici, Methodologie problems encountered in the assay of proteinases in Lewis lung carcinoma, a mouse metastasizing tumor, Tumori 68: 381 (1982).PubMedGoogle Scholar
  45. 45).
    V. Grill, F. Mallardi, S. Zorzet, L. Perissin, and T. Giraldi, Morphological analysis of metastatic potential and antimetastatic drug effects in mice bearing two lines of Lewis lung carcinoma, Clin. Expl. Metastasis 5: 233 (1987).CrossRefGoogle Scholar
  46. 46).
    K. Hellmann, P. G. Salsbury, A. J. Burrage, A. W. Le Serve and S. E. James, Drug-induced inhibition of haematogenously spread metastases, in: “Chemotherapy of cancer dissemination and metastasis,” S. Garattini and G. Franchi, eds., Raven Press, New York (1973).Google Scholar
  47. 47).
    G. H. Heppner, Tumor heterogeneity, Cancer Res. 44: 2259 (1984).PubMedGoogle Scholar
  48. 48).
    C. J. Honsik and L. Olsson, Phenotypic heterogeneity of malignant tumors as revealed by monoclonal antibodies, Invasion Metastasis 2: 249 (1982).Google Scholar
  49. 49).
    J. E. Talmadge, The selective nature of metastasis, Cancer Metastasis Rev. 2: 25 (1983).PubMedCrossRefGoogle Scholar
  50. 50).
    A. Sacchi, A. Corsi, M. Caputo and G. Zupi, In vitro and in vivo selection of two Lewis lung carcinoma cell lines, Tumori 65: 657 (1979).PubMedGoogle Scholar
  51. 51).
    G. Zupi, A. Corsi, A. Sacchi, L. Lassiani and T. Giraldi, Effects of dimethyltriazenes on in vitro Lewis lung carcinoma tumor lines with different metastatic capacity, Invasion Metastasis 4: 179 (1984).PubMedGoogle Scholar
  52. 52).
    G. Sava, T. Giraldi, G. Zupi and A. Sacchi, Effects of antimetastatic dimethyltriazenes in mice bearing Lewis lung carcinoma lines with different metastatic potential, Invasion Metastasis 4: 171 (1984).PubMedGoogle Scholar
  53. 53).
    M. C. Fioretti, P. Fuschiotti, R. Blanchi, M. Allegrucci, U. Grohmann, L. Romani and P. Puccetti, in: “Advances in immunomodulation,” B. Bizzini and E. Bonmassar, eds., Pythagora Press, Roma-Milan (1988).Google Scholar
  54. 54).
    T. Giraldi, G. Sava, S. Zorzet, L. Perissin, P. Piccini, S. Pacor and V. Rapozzi, Tumor metastatic potential following treatment with selective antimetastatic drugs, Clin. Expl. Metastasis 6 (Suppl. 1): 91 (1988).CrossRefGoogle Scholar
  55. 55).
    S. Zorzet, L. Perissin, P. Piccini, V. Rapozzi, S. Pacor, G. Sava and T. Giraldi, Tumour metastatic potential after treatment with selective antimetastatic drugs, Pharmacol. Res. 21: 457 (1989).CrossRefGoogle Scholar
  56. 56).
    S. Zorzet, L. Perissin, V. Rapozzi, S. Pacor, M. G. Rodani, G. Sava and T. Giraldi, Tumor metastatic potential following treatment with selective antimetastatic drugs, Farmaci e Terapia VI (Suppl. 4): 92 (1989).Google Scholar
  57. 57).
    M. Allegrucci, P. Fuschiotti, P. Puccetti, L. Romani and M. C. Fioretti, Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative, Clin. Expl. Metastasis 7: 329 (1989).CrossRefGoogle Scholar
  58. 58).
    G. Sava, T. Giraldi, L. Lassiani and C. Nisi, Metabolism and mechanism of the antileukemic action of isomeric aryldimethyltriazenes, Cancer Treat. Rep. 66: 1751 (1982).PubMedGoogle Scholar
  59. 59).
    G. Sava, T. Giraldi, C. Nisi and G. Bertoli, Prophylactic antimetastatic treatment with aryldimethyltriazenes as adjuvants to surgical tumor removal in mice bearing Lewis lung carcinoma, Cancer Treat. Rep. 66: 115 (1982).PubMedGoogle Scholar
  60. 60).
    T. Giraldi, G. Sava, L. Lassiani and C. Nisi, Selectivity of the mechanism of action of antimetastatic drugs, in: “Current Chemotherapy and Immunotherapy. Proceedings of the 12th International Congress of Chemotherapy. Florence, Italy 19–24 July 1981, Vol. II,” P. Periti and G. Gialdroni Grassi, eds., The American Society for Microbiology, Washington DC U.S.A. (1982).Google Scholar
  61. 61).
    T. Giraldi, G. Sava, R. Cherubino, L. Lassiani, G. Bottiroli and G. Mazzini, Metastasis: mitostatic drugs, in: “The Control of Tumour Growth and its Biological Bases,” W. Davis, C. Maltoni and St. Tanneberger, eds., Akademie-Verlag, Berlin (1983).Google Scholar
  62. 62).
    T. Giraldi, G. Sava and R. Cherubino, Selective antimetastatic action of p-(3,3-dimethyl-l-triazeno)benzoic acid potassium salt (DM-COOK), in: “Proceedings of the 13th International Congress of Chemotherapy, Tom 16,” K. H. Spitzy and K. Karrer, eds., Verlag H. Egermann, Vienna (1983).Google Scholar
  63. 63).
    T. Giraldi, G. Sava, L. Perissin and S. Zorzet, Role of host responses in the drug treatment of metastasis, in: “Cancer Metastasis, Biological and Biochemical Mechanisms and Clinical Aspects,” G. Prodi, L.A. Liotta, P.L. Lollini, S. Garbisa, S. Gorini and K. Hellmann, eds., Plenum Press, New York and London (1987).Google Scholar
  64. 64).
    G. Sava, T. Giraldi, L. Perissin, S. Zorzet, F. Mallardi and V. Grill, Infiltration of liver and brain by tumor cells in leukemic mice: prevention by dimethyltriazenes and cyclophosphamide, Tumori 70: 477 (1984).PubMedGoogle Scholar
  65. 65).
    I. Hrsak, Rudjer Boskovic Institute, Zagreb, Yugoslavia; personal communication.Google Scholar
  66. 66).
    M. Tamaro, L. Dolzani, C. Monti-Bragadin and G. Sava, Mutagenic activity of the dacarbazine analog p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt in bacterial cells, Pharm. Res. Commun. 18: 491 (1986).CrossRefGoogle Scholar
  67. 67).
    G. Sava, T. Giraldi, F. Bartoli-Klugmann, G. Decorti and F. Mallardi, Effects of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia, Eur. J. Cancer Clin. Oncol. 20: 287 (1984).PubMedCrossRefGoogle Scholar
  68. 68).
    G. Sava, T. Giraldi, L. Perissin, S. Zorzet and G. Decorti, Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice, Clin. Expl. Metastasis 5: 27 (1987).CrossRefGoogle Scholar
  69. 69).
    K. Hellmann, Antimetastatic drugs: laboratory to clinic, Clin. Expl. Metastasis 1 (1984).Google Scholar
  70. 70).
    K. Hellmann, J. Gilbert, M. Evans, P. Cassell and R. Taylor, Effect of razoxane on metastases from colorec-tal cancer, Clin. Expl. Metastasis 5: 3 (1987).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Tullio Giraldi
    • 1
  • Laura Perissin
    • 1
  • Sonia Zorzet
    • 1
  • Valentina Rapozzi
    • 1
  1. 1.Istituto di FarmacologiaUniversità di TriesteTriesteItaly

Personalised recommendations